Aberdeen Group
INZY

Aberdeen Group’s Inozyme Pharma INZY Stock Holding History

Aberdeen Group’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-326,758
Closed -$297K – 968
2025
Q1 		$297K Buy
326,758
+156,236
+92% +$217K ﹤0.01% 905
2024
Q4 		$472K Buy
+170,522
New +$649K ﹤0.01% 875

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Aberdeen Group's INZY Position: Q2 2025 in Review

Aberdeen Group sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 326,758 shares — an estimated $297K sold.

Aberdeen Group first reported a position in INZY in Q4 2024 and held it in 2 quarters. The position peaked at $472K in Q4 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Aberdeen Group reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Aberdeen Group sold 326,758 Inozyme Pharma shares in Q2 2025, an estimated $297K.
  • Aberdeen Group first reported a position in Inozyme Pharma in Q4 2024 and held it in 2 quarters.
  • Aberdeen Group's Inozyme Pharma position peaked at $472K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Aberdeen Group's 13F filing for Q2 2025, filed 24 Jul 2025.